Fig. 6: Gastrodin treatment effectively enhances remyelination in EAE mice.

a Schematic depicting EAE model and gastrodin treatment (gastrodin setting, 100 mg/kg ip). IT: initial treatment, PT: Peak treatment. b, c Clinical score in EAE mice treated at 1 dpi (left) or treated at disease peak (right) with gastrodin or vehicle (n = 6–10 mice). d LFB staining of spinal cord sections at 30 dpi (left) and quantification of the demyelinated white matter’s percentage (right, n = 3 mice). Black boxes zoom in are shown below. e Representative images of MBP (green) immunofluorescence in spinal cord sections at 30 dpi (left) and quantification of MBP⁺ area’s percentage (right, n = 3 mice). f Representative images of CC1 (red) and Sox10 (green) immunofluorescence around lesions at 30 dpi (left), and quantification of CC1⁺Sox10⁺ cells/mm² (right, n = 3 mice). White boxes zoom in are shown below. Data are represented as mean ± SEM, Mann–Whitney U in b and c, one-way ANOVA with Tukey in d–f.